ClinicalTrials.gg
RecruitingNCT05797831Updated May 2, 2024

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

A Phase 2/3 interventional study of Navtemadlin and Navtemadlin Placebo in Endometrial Cancer, sponsored by Kartos Therapeutics, Inc.. Recruiting at 83 sites in 17 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
268
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
104th of 591
268 · median 60
Started
2023
with 53 others
Phase 2/3
Only one
of the 715
Primary completion
2025-08
later than 28 of 283 live
Registered
538th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 104th largest by planned enrollment of the 591 interventional ones that give a count, is one of 54 that started in 2023, is the only one in phase 2/3, reaches primary completion later than 28 of the 283 other live ones, and was the 538th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

190 more — sign in →

All 195 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy.

The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • navtemadlin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 0-1
  • or cytologically confirmed diagnosis of endometrial cancer documented as TP53WT
  • Subjects with advanced or recurrent disease must have completed a single line of up to 6 cycles of taxane-platinum based chemo and achieved a CR or PR per V1.1
  • Adequate hematologic, hepatic and renal function (within 14 days)

Exclusion criteria

Exclusion Criteria:

  • Has any sarcomas or small-cell carcinomas with neuroendocrine differentiation
  • Prior immune therapy, cytokine therapy, or any therapy (within 28 days)
  • Indwelling surgical drains
  • Grade 2 or higher prolongation
  • History of major organ transplant
  • History of bleeding diathesis; major hemorrhage or intracranial hemorrhage (within 24 weeks)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
268 participants (estimated)

Study arms

  • Experimental
    Part 1 Arm 1

    Navtemadlin administered orally at 180 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.

    Drug: Navtemadlin

  • Experimental
    Part 1 Arm 2

    Navtemadlin administered orally at 240 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.

    Drug: Navtemadlin

  • No intervention
    Part 1 Arm 3

    Observational control ("watch and wait") on a 28-day cycle.

  • Experimental
    Part 2 Arm A

    Navtemadlin administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.

    Drug: Navtemadlin

  • Experimental
    Part 2 Arm B

    Navtemadlin administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.

    Drug: Navtemadlin

  • Placebo comparator
    Part 2 Arm C

    Placebo administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.

    Drug: Navtemadlin Placebo

  • Placebo comparator
    Part 2 Arm D

    Placebo administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.

    Drug: Navtemadlin Placebo

Interventions

  • Navtemadlin is an experimental MDM2 anticancer drug taken by mouth

    Also known as: KRT-232

  • DrugNavtemadlin Placebo

    Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth

06

What researchers measure

Primary outcomes

  1. Part 1: To determine the navtemadlin Phase 3 dose

    Safety review committee (SRC) will determine the navtemadlin Phase 3 dose for Part 2 based on safety data from Part 1

    Time frame: 12 months

  2. Part 2: To compare progression-free (PFS) survival by independent review committee (IRC) between navtemadlin and placebo

    PFS defined as the time from randomization to disease progression by IRC or death, whichever occurs first

    Time frame: 50 months

Secondary outcomes

  1. Part 1: To evaluate the treatment effect of navtemadlin on PFS by IRC and investigator assessment

    PFS defined as the time from randomization to disease progression by IRC/investigator assessment or death, whichever occurs first

    Time frame: 50 months

  2. Part 2: To evaluate the treatment effect of navtemadlin on the time to first subsequent treatment (TFST)

    TFST defined as the time from randomization to initiation of first subsequent anticancer therapy or death, whichever occurs first

    Time frame: 50 months

  3. Parts 1 and 2: To determine the pharmacokinetic (PK) profile of navtemadlin

    Will determine the Maximum observed concentration (Cmax)

    Time frame: 1 day

  4. Parts 1 and 2: To determine the pharmacokinetic (PK) profile of navtemadlin

    Will determine the area under the plasma concentration versus time curve (AUC)

    Time frame: 1 day

  5. Parts 1 and 2: To determine the pharmacokinetic (PK) profile of navtemadlin

    Will determine the time of maximum plasma concentration (Tmax)

    Time frame: 1 day

  6. Parts 1 and 2: To evaluate the treatment effect of navtemadlin on the disease control rate (DCR)

    Best response of complete response (CR), partial response (PR) or stable disease (SD) by IRC/investigator assessment among subjects with PR as best response from prior chemotherapy

    Time frame: 50 months

07

Study locations

83 of 83 sites recruiting
  • Kaiser Permanente Center
    Vallejo, California 94589, United States
    Recruiting
  • Northside Hospital
    Atlanta, Georgia 30342, United States
    Recruiting
  • St. Joseph
    Savannah, Georgia 31405, United States
    Recruiting
  • Dr. Sudarshan K. Sharma, Ltd.
    Hinsdale, Illinois 60521, United States
    Recruiting
  • Parkview Research Center
    Fort Wayne, Indiana 46845, United States
    Recruiting
  • Indiana University
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Maryland Oncology Hematology, P.A.
    Silver Spring, Maryland 20904, United States
    Recruiting
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
    Recruiting
  • Washington University School of Medicine
    Saint Louis, Missouri 63108, United States
    Recruiting
  • Women's Cancer Center of Nevada
    Las Vegas, Nevada 89106, United States
    Recruiting
  • Good Samaritan Hospital Medical Center
    West Islip, New York 11795, United States
    Recruiting
  • FirstHealth Carolinas
    Pinehurst, North Carolina 28374, United States
    Recruiting
  • OhioHealth Institute
    Columbus, Ohio 43214, United States
    Recruiting
  • Oklahoma Cancer Specialists and Research Institute
    Tulsa, Oklahoma 74146, United States
    Recruiting
  • Oncology Associates of Oregon
    Eugene, Oregon 97401, United States
    Recruiting
  • Northwest Cancer Specialists
    Portland, Oregon 97227, United States
    Recruiting
  • Texas Oncology-Austin Central
    Austin, Texas 78745, United States
    Recruiting
  • Texas Oncology-Fort Worth Cancer Center
    Fort Worth, Texas 76104, United States
    Recruiting
  • Texas Oncology-San Antonio Medical Center
    San Antonio, Texas 78130, United States
    Recruiting
  • University Hospital Graz, Department of Gynecology and Obstetrics
    Graz, 8036, Austria
    Recruiting
  • Medizinische Universität Innsbruck
    Innsbruck, 6020, Austria
    Recruiting
  • Medizinische Universität Wien
    Vienna, 1090, Austria
    Recruiting
  • Cross Cancer Institute
    Edmonton, T6G 1Z2, Canada
    Recruiting
  • CHUM - University of Montreal Hospital Centre
    Montreal, H2X 3E4, Canada
    Recruiting
  • Odense University Hospital
    Odense, DK-5000, Denmark
    Recruiting
  • Tartu University Hospital
    Tartu, 50406, Estonia
    Recruiting
  • Kuopio University Hospital
    Kuopio, 70200, Finland
    Recruiting
  • Turku University Hospital
    Turku, 20520, Finland
    Recruiting
  • LTD High Technology hospital Medcenter
    Batumi, 6000, Georgia
    Recruiting
  • American Hospital Network LLC
    Tbilisi, 0102, Georgia
    Recruiting
  • Caucasus Medical Centre
    Tbilisi, 0186, Georgia
    Recruiting
  • National Institute of Oncology
    Budapest, H-1122, Hungary
    Recruiting
  • University of Debrecen Clinical Center
    Debrecen, 4032, Hungary
    Recruiting
  • Rambam Medical Center
    Haifa, Rambam Medical Center, Israel
    Recruiting
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
    Recruiting
  • Sourasky Medical Center
    Tel-Aviv, 6423906, Israel
    Recruiting
  • A.O. Cannizzaro
    Catania, 95126, Italy
    Recruiting
  • IRCCS Istituto Romangolo per lo Studio dei Tumori "Dino Amadori"
    Forli, 47014, Italy
    Recruiting
  • Ospedale Policlinico San Martino
    Genoa, 16132, Italy
    Recruiting
  • ASST di Lecco-Ospedale Alessandro Manzoni
    Lecco, 23900, Italy
    Recruiting
  • Ospedale San Luca
    Lucca, 55100, Italy
    Recruiting
  • Osp. Niguarda
    Milan, 20162, Italy
    Recruiting
  • University Hospital of Parma
    Parma, 43126, Italy
    Recruiting
  • Ospedale Guglielmo da Saliceto
    Piacenza, 29121, Italy
    Recruiting
  • Ospedale di Prato S. Stefano
    Prato, 59100, Italy
    Recruiting
  • Ospedale Santa Maria delle Croci
    Ravenna, 48121, Italy
    Recruiting
  • "Azienda Unità Sanitaria Locale della Romagna - Hospital ""Infermi"" of Rimini Oncology Department"
    Rimini, 47923, Italy
    Recruiting
  • Policlinico Umberto
    Rome, 00161, Italy
    Recruiting
  • Ospedale Filippo Del Ponte
    Varese, 21110, Italy
    Recruiting
  • Health Sciences Kaunas Clinics
    Kaunas, LT-45434, Lithuania
    Recruiting
  • Nation Cancer Institute of Lithuania, Vilnius
    Vilnius, LT-08660, Lithuania
    Recruiting
  • Southern Hospital Sorlandet
    Kristiansand, 4604, Norway
    Recruiting
  • Oslo University Hospital HF
    Oslo, 0379, Norway
    Recruiting
  • Sykehusapotek Nord Tromsø
    Tromsø, 9038, Norway
    Recruiting
  • Białostockie Centrum Onkologii
    Bialystok, 15-027, Poland
    Recruiting
  • Szpitale Pomorskie
    Gdansk, 80-210, Poland
    Recruiting
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, 80-214, Poland
    Recruiting
  • NIO-PIB Oddzial w Gliwicach
    Gliwice, 44-102, Poland
    Recruiting
  • Centrum Badań klinicznych Jagiellońskie Centrum Innowacji
    Kraków, 31-115, Poland
    Recruiting
  • Siedleckie Centrum Onkologii
    Olsztyn, 10-228, Poland
    Recruiting
  • Uniwersytecki Szpital
    Poznan, 60-569, Poland
    Recruiting
  • NIO-PIB Klinika Gine-Onk
    Warsaw, 02-781, Poland
    Recruiting
  • Lower Silesian Oncology, Pulmonology and Hematology Center, Department of Oncological Gynecology
    Wroclaw, 53-413, Poland
    Recruiting
  • Bucharest CF2 Hospital
    Bucharest, 012244, Romania
    Recruiting
  • Ovidius Clinical Hospital SRL
    Constanta, 905900, Romania
    Recruiting
  • Onco Clinic Consult S.A.
    Craiova, 200094, Romania
    Recruiting
  • Oncology Center "Sf. Nectarie"
    Craiova, 200542, Romania
    Recruiting
  • Gral Medical S.R.L. - Oncofort Hospital
    Piteşti, 110283, Romania
    Recruiting
  • Oncocenter, Oncology Clinic SRL
    Timisoara, 300166, Romania
    Recruiting
  • SC Oncomed SRL
    Timisoara, 300239, Romania
    Recruiting
  • Institute of Oncology Ljubljana
    Ljubljana, 1000, Slovenia
    Recruiting
  • University Clinical Center Maribor
    Maribor, 2000, Slovenia
    Recruiting
  • CHUAC (Hospital de Coruña)
    A Coruna, 15006, Spain
    Recruiting
  • Hospital del Mar
    Barcelona, 08003, Spain
    Recruiting
  • Hospital Galdakao-Usansolo
    Galdakao, 48960, Spain
    Recruiting
  • Hospital Universitario de Jaen
    Jaen, 23007, Spain
    Recruiting
  • H.G.U. Jerez de la Frontera
    Jerez de la Frontera, 11407, Spain
    Recruiting
  • Hospital U Insular de GC
    Las Palmas, 35016, Spain
    Recruiting
  • Hospital de Leon
    Leon, 24008, Spain
    Recruiting
  • HCU Santiago de Compostela
    Santiago de Compostela, 15706, Spain
    Recruiting
  • Hospital Universitario de Valme
    Seville, 41014, Spain
    Recruiting
  • Linkoping University Hospital
    Linköping, 581 85, Sweden
    Recruiting
  • Karolinska University Hospital
    Stockholm, SE-171 76, Sweden
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Aug 2025, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2023
First posted
Apr 4, 2023
StartActual
Jul 17, 2023
Primary completionEst.
Aug 2025
CompletionEst.
Jul 2027
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05797831
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Responsible party
Sponsor
First posted
Apr 4, 2023
Start date
Jul 17, 2023
Primary completion
Aug 2025 (estimated)
Completion
Jul 2027 (estimated)
Last update
May 2, 2024

Study contacts

John Mei
Contact
jmei@kartosthera.com
650-542-0136

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navtemadlin

Start the discussion